Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BLFS 
BioLife Solutions Inc (BLFS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/04/2025: BLFS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $31.5
1 Year Target Price $31.5
| 7 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -20.62% | Avg. Invested days 37 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.34B USD | Price to earnings Ratio - | 1Y Target Price 31.5 |
Price to earnings Ratio - | 1Y Target Price 31.5 | ||
Volume (30-day avg) 9 | Beta 1.93 | 52 Weeks Range 19.10 - 29.62 | Updated Date 11/4/2025 |
52 Weeks Range 19.10 - 29.62 | Updated Date 11/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.4 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-06 | When - | Estimate -0.0113 | Actual - |
Profitability
Profit Margin -5.92% | Operating Margin (TTM) -4.41% |
Management Effectiveness
Return on Assets (TTM) -0.8% | Return on Equity (TTM) -5.66% |
Valuation
Trailing PE - | Forward PE 285.71 | Enterprise Value 1183274416 | Price to Sales(TTM) 14.28 |
Enterprise Value 1183274416 | Price to Sales(TTM) 14.28 | ||
Enterprise Value to Revenue 12.66 | Enterprise Value to EBITDA 67.84 | Shares Outstanding 47905265 | Shares Floating 40101018 |
Shares Outstanding 47905265 | Shares Floating 40101018 | ||
Percent Insiders 2.01 | Percent Institutions 103.09 |
Upturn AI SWOT
BioLife Solutions Inc
Company Overview
History and Background
BioLife Solutions Inc. was founded in 1997. The company develops, manufactures, and markets biopreservation media and related equipment for cells, tissues, and organs. It has grown through organic expansion and strategic acquisitions to offer a broader portfolio of solutions.
Core Business Areas
- Biopreservation Media: BioLife's core business, involves the development and distribution of proprietary biopreservation media products like CryoStoru00ae and HypoThermosolu00ae used to preserve cells and tissues during freezing and thawing processes.
- Bioproduction Equipment: This segment includes the Stratacooleru00ae line of controlled-rate freezers and ThawSTARu00ae automated thawing systems used in cell and gene therapy manufacturing processes.
- Cell Processing Platform: Includes automated fill-finish instrumentation and cryogenic freezers.
Leadership and Structure
Mike Rice is the current Chairman & CEO. The company has a functional organizational structure with departments dedicated to R&D, manufacturing, sales, marketing, and finance. A board of directors oversees management.
Top Products and Market Share
Key Offerings
- CryoStoru00ae: A proprietary line of cryopreservation media used to protect cells during freezing. Competitors include STEMCELL Technologies and Cook Regentec. Market share is estimated at 60% in clinical biopreservation media.
- HypoThermosolu00ae: A hypothermic preservation media used to maintain cells at refrigerated temperatures. Competitors include STEMCELL Technologies and Cook Regentec. Revenue from this product contribute to overall biopreservation media segment revenue.
- ThawSTARu00ae: Automated thawing systems for cryopreserved cells. Competitors include Asymptote (GE Healthcare) and MedCision. Revenue from this product contribute to overall bioproduction equipment segment revenue.
Market Dynamics
Industry Overview
The biopreservation industry is experiencing rapid growth driven by the increasing demand for cell and gene therapies, regenerative medicine, and personalized medicine. The market is characterized by innovation, consolidation, and regulatory scrutiny.
Positioning
BioLife Solutions is positioned as a leading provider of biopreservation media and related equipment, with a strong reputation for quality and innovation. Its competitive advantage lies in its proprietary technologies, established customer base, and comprehensive product portfolio.
Total Addressable Market (TAM)
The total addressable market (TAM) for biopreservation media and related equipment is estimated to be in the billions of dollars. BioLife Solutions is well positioned to capture a significant share of this market.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Proprietary technologies
- Established customer base
- Comprehensive product portfolio
- Experienced management team
Weaknesses
- Dependence on cell and gene therapy market growth
- Relatively small size compared to larger competitors
- Fluctuations in product revenue streams.
Opportunities
- Expanding into new geographic markets
- Developing new biopreservation solutions
- Acquiring complementary technologies
- Partnering with cell and gene therapy companies
Threats
- Increased competition
- Regulatory changes
- Economic downturn
- Technological obsolescence
Competitors and Market Share
Key Competitors
- STEM
- COOK
Competitive Landscape
BioLife Solutions has a competitive advantage in its proprietary technologies and established customer base. However, it faces competition from larger companies with greater resources.
Major Acquisitions
SAVSU Technologies
- Year: 2019
- Acquisition Price (USD millions): 92
- Strategic Rationale: The acquisition of SAVSU Technologies expanded BioLife Solutions' portfolio of cold chain solutions for cell and gene therapies.
Growth Trajectory and Initiatives
Historical Growth: BioLife Solutions Inc. has experienced significant growth in recent years driven by the increasing demand for biopreservation solutions. This growth has been achieved through organic expansion and strategic acquisitions.
Future Projections: Analyst estimates project continued revenue growth for BioLife Solutions Inc. driven by the expanding cell and gene therapy market and the company's strong market position.
Recent Initiatives: Recent initiatives include new product launches, strategic partnerships, and acquisitions to expand the company's product portfolio and geographic reach.
Summary
BioLife Solutions is a key player in the biopreservation market, benefiting from the growth of cell and gene therapies. The company's strengths lie in its proprietary technologies and established customer base. However, it needs to be aware of increasing competition and regulatory changes and focus on continuing acquisitions to further increase market share.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is approximate and based on available estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioLife Solutions Inc
Exchange NASDAQ | Headquaters Bothell, WA, United States | ||
IPO Launch date 1989-11-22 | CEO & Chairman Mr. Roderick de Greef | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 159 | Website https://www.biolifesolutions.com |
Full time employees 159 | Website https://www.biolifesolutions.com | ||
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.